These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 19440560)
41. Recent trends in brand-name and generic drug competition. Grabowski H; Long G; Mortimer R J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785 [TBL] [Abstract][Full Text] [Related]
42. [Blocking of generic drugs must be fought]. Kringlen E Tidsskr Nor Laegeforen; 2013 Oct; 133(19):2032. PubMed ID: 24129531 [No Abstract] [Full Text] [Related]
43. The economics of pediatric formulation development for off-patent drugs. Milne CP; Bruss JB Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801 [TBL] [Abstract][Full Text] [Related]
44. Different facets of competition in the pharmaceutical sector: preliminary findings of the European Commission's sector inquiry into pharmaceuticals. Borkowski F Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):1-5. PubMed ID: 20107914 [TBL] [Abstract][Full Text] [Related]
47. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Magazzini L; Pammolli F; Riccaboni M Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754 [TBL] [Abstract][Full Text] [Related]
48. Variations in time of market exclusivity among top-selling prescription drugs in the United States. Wang B; Liu J; Kesselheim AS JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700 [No Abstract] [Full Text] [Related]
49. Congress works to permit 'biosimilar' drugs very soon. Carroll J Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559 [No Abstract] [Full Text] [Related]
50. Market watch: Sales of biologics to show robust growth through to 2013. Goodman M Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035 [No Abstract] [Full Text] [Related]
51. Skies darken over drug companies. Holmes D Lancet; 2012 May; 379(9829):1863-4. PubMed ID: 22616103 [No Abstract] [Full Text] [Related]
52. [What drug companies actually do]. Tonby K Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137 [No Abstract] [Full Text] [Related]
53. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right? Downing NS JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529 [No Abstract] [Full Text] [Related]
54. European Court of Justice. Baeyens A Eur J Health Law; 2020 May; 27(2):180-186. PubMed ID: 33652402 [No Abstract] [Full Text] [Related]
55. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing? Sturm AC Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287 [No Abstract] [Full Text] [Related]
56. Pharma industry in India. Sundaram VM Drug News Perspect; 2008; 21(1):59-63. PubMed ID: 18301810 [TBL] [Abstract][Full Text] [Related]
57. Patent indicators: a window to pharmaceutical market success. Guo Y; Hu Y; Zheng M; Wang Y Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022 [TBL] [Abstract][Full Text] [Related]
59. [Free trade agreements make the drugs more expensive]. Jeppsson A Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499 [No Abstract] [Full Text] [Related]